SCHEMBL2591063

SCHEMBL2591063

c1ccc(Nc2nc(Nc3ccccc3)c3ccccc3n2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 10/20 1.00
SLC2A1 P11166 1/20 0.69
SMN1; SMN2 Q16637 2/20 0.65
TAAR1 Q96RJ0 2/20 0.65
POLB P06746 1/20 0.65
HTT P42858 1/20 0.65
NPC1 O15118 1/20 0.64
TP53 P04637 1/20 0.64
PKM P14618 1/20 0.64
ALOX15 P16050 1/20 0.64
TSHR P16473 1/20 0.64
NFKB1 P19838 1/20 0.64
MAPK1 P28482 1/20 0.64
RAB9A P51151 1/20 0.64
NFKB2 Q00653 1/20 0.64
RELA Q04206 1/20 0.64
MEN1 O00255 1/20 0.64
KMT2A Q03164 1/20 0.64
ABCG2 Q9UNQ0 1/20 0.64
AURKA O14965 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6039677 0.98 NPY5R (0.96) NPY5RSLC2A1SMN1; SMN2TAAR1POLB
SCHEMBL8901062 0.92 NPY5R (0.84) NPY5RSLC2A1SMN1; SMN2TAAR1POLB
SCHEMBL8898077 0.92 NPY5R (0.84) NPY5RSLC2A1TSHRMAPK1MEN1
Hydrochloric Acid SCHEMBL8900449 0.90 NPY5R (0.81) NPY5RSLC2A1SMN1; SMN2TAAR1POLB
Hydrochloric Acid SCHEMBL8900034 0.90 NPY5R (0.81) NPY5RSLC2A1SMN1; SMN2TAAR1POLB
SCHEMBL8890945 0.90 NPY5R (1.00) NPY5RSLC2A1SMN1; SMN2HTTTP53
SCHEMBL8890555 0.90 NPY5R (1.00) NPY5RSLC2A1TAAR1POLBNPC1
SCHEMBL8890734 0.90 NPY5R (0.81) NPY5RSLC2A1SMN1; SMN2TAAR1POLB
Hydrochloric Acid SCHEMBL8898758 0.90 NPY5R (0.81) NPY5RSLC2A1SMN1; SMN2TAAR1POLB
Hydrochloric Acid SCHEMBL8900357 0.89 NPY5R (0.97) NPY5RSLC2A1SMN1; SMN2POLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3108900-B1 PROTOTYPE SYSTEMS OF THERANOSTIC BIOMARKERS FOR IN VIVO MOLECULAR MANAGEMENT OF CANCER EPOS IASIS RES AND DEVELOPMENT LTD (CY) 2019-04-24 EP claimed
WO-1997020822-A1 QUINAZOLIN-2,4-DIAZIRINES AS NPY RECEPTOR ANTAGONIST NOVARTIS AG (CH) 1997-06-12 WO claimed
EP-2566480-A2 METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE California Institute of Technology (US) 2013-03-13 EP disclosed
WO-2011140527-A2 METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE CALIFORNIA INSTITUTE OF TECHNOLOGY AND THE UNIVERSITY OF KANSAS (US) 2011-11-10 WO disclosed